NANOBIOTIX (EPA:NANO)

BRIEF

published on 06/24/2025 at 12:39, 1 year 4 months ago

Goldman Sachs Crosses Stake Threshold in Nanobiotix

Stock Market Acquisition Of Shares Goldman Sachs Threshold Crossing NANOBIOTIX
BRIEF

published on 06/10/2025 at 22:20, 1 year 4 months ago

Number of Shares and Voting Rights of Nanobiotix

Euronext Paris Voting Rights Actions Nasdaq NANOBIOTIX
PRESS RELEASE

published on 06/10/2025 at 22:15, 1 year 4 months ago

Voting Rights and Shares Capital of the Company
Nanobiotix discloses voting rights and shares capital. The company is a biotechnology pioneer with disruptive therapeutic approaches. Visit www.nanobiotix.com for more info

Voting Rights Biotechnology Shares Capital NANOBIOTIX Therapeutic Approaches
BRIEF

published on 05/21/2025 at 22:20, 1 year 5 months ago

Nanobiotix Reports Q1 2025 Achievements and Financial Status

Biotechnology Financial Update NANOBIOTIX JNJ-1900 Cancer Trials
PRESS RELEASE

published on 05/21/2025 at 22:15, 1 year 5 months ago

Nanobiotix Provides First Quarter 2025 Operational and Financial Update
Nanobiotix provides operational and financial update for Q1 2025, including CONVERGE study dosing, financial strengthening, and €39.8M cash reserves as of March 31, 2025

Operational Update Financial Update Cash Reserves NANOBIOTIX CONVERGE Study
BRIEF

published on 04/14/2025 at 22:20, 1 year 6 months ago

Nanobiotix: Monthly update of voting rights and shares

Share Capital Voting Rights Euronext Nasdaq NANOBIOTIX
PRESS RELEASE

published on 04/14/2025 at 22:15, 1 year 6 months ago

Voting Rights and Shares Capital of the Company
Nanobiotix reports voting rights and shares capital updates. The late-stage biotech company aims to improve treatment outcomes through innovative therapies

Voting Rights Shares Capital Biotechnology Company NANOBIOTIX Treatment Outcomes
BRIEF

published on 03/27/2025 at 21:20, 1 year 7 months ago

Nanobiotix Unveils Phase 1 Data on NSCLC Therapy

NSCLC NBTXR3 Phase 1 Study Radioenhancer Clinical Trial Data
PRESS RELEASE

published on 03/27/2025 at 21:15, 1 year 7 months ago

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
Nanobiotix announces first data from the completed dose escalation part of a Phase 1 study evaluating NBTXR3 (JNJ-1900) as a 2L+ therapy for patients with locally advanced NSCLC. The study shows favorable safety and injection feasibility, with promising survival data

NSCLC NANOBIOTIX NBTXR3 Phase 1 Study Dose Escalation
BRIEF

published on 03/20/2025 at 21:20, 1 year 7 months ago

Nanobiotix Unveils Phase 1 Results at European Lung Cancer Congress

Biotechnology NANOBIOTIX Lung Cancer Phase 1 JNJ-1900

Published on 10/30/2026 at 23:35, 1 day 13 hours ago

Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 1 day 13 hours ago

Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 20:47, 1 day 16 hours ago

CoTec Holdings Corp. Comments on Share Trading
Published on 10/30/2026 at 19:00, 1 day 17 hours ago

Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 1 day 21 hours ago

Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split

View all ACCESSWIRE

Published on 11/01/2026 at 10:35, 2 hours 15 minutes ago

Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 7 hours 50 minutes ago

2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 20 hours 15 minutes ago

SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 1 day 14 hours ago

EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 22:30, 1 day 14 hours ago

/C O R R E C T I O N - OCI Global/

View all EQS

Published on 10/30/2026 at 23:00, 1 day 13 hours ago

BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 20:42, 1 day 16 hours ago

TINC and PMV invest in Storm Group (B)
Published on 10/30/2026 at 18:00, 1 day 18 hours ago

2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 2 days ago

Capital increase through exercise of subscription rights
Published on 10/30/2026 at 08:45, 2 days 4 hours ago

Share buyback

View all LES ECHOS COMFI WIRE

News